Aclaris Therapeutics (ACRS) Accumulated Expenses (2014 - 2026)

Aclaris Therapeutics' Accumulated Expenses history runs 13 years deep, the most recent figure standing at $2.0 million for Q1 2026.

• In Q1 2026, Accumulated Expenses rose 17.83% year-over-year to $2.0 million; the TTM figure through Mar 2026 stood at $2.0 million (up 17.83% YoY), while the FY2025 annual figure was $8.8 million, up 76.56% from the prior year.
• Accumulated Expenses was $2.0 million for Q1 2026 at Aclaris Therapeutics, down from $8.8 million in the prior quarter.
• In the past five years, Accumulated Expenses ranged from a high of $19.4 million in Q4 2023 to a low of $502000.0 in Q3 2024.
• Historically, Accumulated Expenses has averaged $6.2 million across 5 years, with a median of $5.0 million in 2024.
• The sharpest annual moves came in 2024 and 2025: Accumulated Expenses slumped 96.69% in 2024, then surged 1849.0% in 2025.
• A 5-year view of Accumulated Expenses shows it stood at $8.7 million in 2022, then soared by 123.49% to $19.4 million in 2023, then plunged by 74.4% to $5.0 million in 2024, then surged by 76.56% to $8.8 million in 2025, then slumped by 76.77% to $2.0 million in 2026.
• The last three Accumulated Expenses figures came in at $2.0 million (Q1 2026), $8.8 million (Q4 2025), and $9.8 million (Q3 2025), per Business Quant data.